Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijerph17103664 http://scihub22266oqcxt.onion/10.3390/ijerph17103664 32456064!7277613!32456064     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Environ+Res+Public+Health 2020 ; 17 (10): ä Nephropedia Template TP {{tp|p=32456064|t=2020. Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis |pdf=|usr=}}{{32456064}} gab.com Text Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis JO: Int J Environ Res Public Health http://www.kidney.de/pget.php?&tw=1&pmid=32456064 #FOAvip Patients with diabetes have been reported to have enhanced susceptibility to severe or fatal COVID-19 infections, including a high risk of being admitted to intensive care units with respiratory failure and septic complications. Given the global prevalence of diabetes, affecting over 450 million people worldwide and still on the rise, the emerging COVID-19 crisis poses a serious threat to an extremely large vulnerable population. However, the broad heterogeneity and complexity of this dysmetabolic condition, with reference to etiologic mechanisms, degree of glycemic derangement and comorbid associations, along with the extensive sexual dimorphism in immune responses, can hamper any patient generalization. Even more relevant, and irrespective of glucose-lowering activities, DPP4 inhibitors and GLP1 receptor agonists may have a favorable impact on the modulation of viral entry and overproduction of inflammatory cytokines during COVID-19 infection, although current evidence is limited and not univocal. Conversely, SGLT2 inhibitors may increase the likelihood of COVID-19-related ketoacidosis decompensation among patients with severe insulin deficiency. Mindful of their widespread popularity in the management of diabetes, addressing potential benefits and harms of novel antidiabetic drugs to clinical prognosis at the time of a COVID-19 pandemic deserves careful consideration. Twit Text FOAVip Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis ????Int J Environ Res Public Health http://www.kidney.de/pget.php?&tw=1&pmid=32456064 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32456064 #FOAvip English Wikipedia <ref>{{Cite pmid|32456064}}</ref> Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis #MMPMID32456064 Mirabelli M; Chiefari E; Puccio L; Foti DP; Brunetti A Int J Environ Res Public Health 2020[May]; 17 (10): ä PMID32456064show ga Patients with diabetes have been reported to have enhanced susceptibility to severe or fatal COVID-19 infections, including a high risk of being admitted to intensive care units with respiratory failure and septic complications. Given the global prevalence of diabetes, affecting over 450 million people worldwide and still on the rise, the emerging COVID-19 crisis poses a serious threat to an extremely large vulnerable population. However, the broad heterogeneity and complexity of this dysmetabolic condition, with reference to etiologic mechanisms, degree of glycemic derangement and comorbid associations, along with the extensive sexual dimorphism in immune responses, can hamper any patient generalization. Even more relevant, and irrespective of glucose-lowering activities, DPP4 inhibitors and GLP1 receptor agonists may have a favorable impact on the modulation of viral entry and overproduction of inflammatory cytokines during COVID-19 infection, although current evidence is limited and not univocal. Conversely, SGLT2 inhibitors may increase the likelihood of COVID-19-related ketoacidosis decompensation among patients with severe insulin deficiency. Mindful of their widespread popularity in the management of diabetes, addressing potential benefits and harms of novel antidiabetic drugs to clinical prognosis at the time of a COVID-19 pandemic deserves careful consideration. |*Pandemics[MESH] |Betacoronavirus/*isolation & purification[MESH] |Blood Glucose[MESH] |COVID-19[MESH] |Coronavirus Infections/epidemiology/*physiopathology/virology[MESH] |Diabetes Mellitus[MESH] |Humans[MESH] |Hypoglycemic Agents/adverse effects/*therapeutic use[MESH] |Insulin[MESH] |Pneumonia, Viral/epidemiology/*physiopathology/virology[MESH]Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-(epmc).pdf DeepDyve Pubget Overpricing